Holotyping Without Borders – Holotype HLA v2 Experiences Within and…

Marcello Scala, MSc VP Sales Operations, EMEA Asia

Having dominated a NGS-based HLA Typing landscape in Europe for a past several years, a expansion Omixon has celebrated outward of Europe, fueled by adoption in a African continent, Russia and mixed labs in a Middle East has been quite satisfying.

Global molecular diagnostics association Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce currently that Holotype HLA and other Omixon products will be featured in 9 print presentations constructed by Holotype business during a annual assembly of a European Federation for Immunogenetics (EFI) in Venice, Italy. Additionally, Omixon’s Lunch Symposium on Thursday will concentration on a practice of existent Holotype HLA for clinical and registry functions within and outward a European Union.

The energy of Holotype HLA will be demonstrated in several posters, including a marker of novel nothing alleles; Mette Christiansen et al. (P30) who rescued a novel transformation in HLA-B*08, Vera Siffnerova et al. (P87) who used a singular phasing capabilities of Holotype HLA to solve a novel HLA-C*02 unresolvable by SBT and Amalia Dinou (P146) who showed that HLA Twin could solve a phasing ambiguity as HLA-B*44:18, 50:01, that was formerly unresolvable by other methods. Of special seductiveness is a print from Eszter Lazar-Molnar (P115), who investigated severe samples with Loss of Heterozygosity (LoH) in Acute Myeloid Leukemia (AML) – critical for bargain a expansion of expansion shun from defence response. In these intriguing samples, a singular capabilities and facilities of Holotype HLA and HLA Twin were used to establish a HLA forms even in situations of impassioned imbalance (~10%) in a DNA representation due to LoH.

Omixon’s Lunch Symposium, patrician “HLA Typing but Borders” on May 10 will underline 3 patron knowledge stories from within and outward Europe. Vera Siffnerova from a UHKT in Prague will benefaction on their knowledge with Holotype HLA V2 for branch dungeon transplantation, while Dr. Elena Shagimardanova from Kazan Federal University in Russia will benefaction on their purpose as Russian colonize in a doing of Holotype HLA and NGS for HLA registry typing and Derrick Nelson from a South African National Blood Service will benefaction on a improvements between a Holotype HLA V1 and v2 as they demeanour to scale adult their branch dungeon typing to 6,000 samples per year for registry typing. Omixon’s CEO Dr. Peter Meintjes will finish a event with announcements about a continual improvements to Holotype HLA, including a timeline for rising Holotype HLA v3 as RUO and CE-IVD, and dual new authority pack products for ABO Blood Group Typing and MICA genotyping.

Marcello Scala, VP Sales, EMEA Asia Omixon says, “Having dominated a NGS-based HLA Typing landscape in Europe for a past several years, a expansion Omixon has celebrated outward of Europe, fueled by adoption in a African continent, Russia and mixed labs in a Middle East has been quite satisfying. We are gay by a continued unrestrained that business have for Holotype HLA to support their workflows for bone pith transplantation, plain organ transplantation and registry typing and how frequently a products and a people are endorsed to new labs wishing to adopting this sparkling technology”.

Omixon during EFI 2018

May 09 – May 12 | Omixon will be exhibiting during Booth #15/16 via a conference

May 09 – May 12 | HLA Twin Live Software Demos during Booth #15/16

May 09, 9am – 12pm | Distributor Workshop

May 09, 1pm – 5pm | Interactive User Group Meeting

May 10, 1.30pm-2.30pm | Holotyping Without Borders – Holotype HLA v2 Experiences Within and from Outside a EU for a Benefit of a Wider Transplant Community

Omixon Featured in Posters

P30 | Mette Christiansen et al. (2018) – Discovery of a novel HLA-B*08 nothing allele in a danish kidney transplant recipient

P87 | Vera Siffnerova et al. (2018) – Detection of a novel allele with NGS has never been easier

P115 | Eszter Lazar-Molnar et al. (2018) – Loss of heterozygosity in a HLA segment and attraction of HLA typing methods for detecting underrepresented alleles

P135 | Mehdi Alizadeh et al. (2018) – From a representation to donor / target compatibility: A extensive operation of laboratory reagents and apparatus for NGS-based genotyping of exemplary and non-classical HLA genes

P146 | Amalia Dinou et al. (2018) – Definitive fortitude of HLA typing errors and ambiguities by NGS typing

P165 | Thomas M.C. Binder et al. (2018) – A new surprising HLA-DQA1 allele: DQA1*01Q:NEW

P168 | Stana Tokić et al. (2018) – HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 AND -DPB1 allele and haplotype frequencies tangible by Next era Sequencing in a race of East Croatia blood donor

P172 | Thomas M.C. Binder et al. (2018) – HLA-DRB1*03:24 – A DRB1*03:01-like Exon 2 method in standard DRB1*13:02- haplotype

About Omixon

Omixon is a tellurian molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and investigate laboratories. Omixon’s flagship product, Holotype HLA, is a world’s heading NGS-based HLA genotyping product that delivers a many accurate high-resolution HLA genotyping available, and is used in some-more than 45 hospitals worldwide. Omixon’s investigate software, HLA Explore analyzes information from any sequencing record and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded investigate module with a product tube focused on pre- and post-transplantation, and HLA genotyping applications over transplantation. For some-more information, revisit http://www.omixon.com